Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
ABOS Interest Income
Income earned on cash, deposits, and investments held by the company.
Acumen Pharmaceuticals, Inc.NASDAQ: ABOS
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $1.06M fell 56.9% year over year, behind the -52.7% change in trailing-twelve-month interest income. Sequentially, it fell 19.5% from the prior quarter. Over 3 fiscal years it compounded at +46.0% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -56.9% toward the trailing-twelve-month pace of -52.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 7.45M USD
- Year-over-year change
- -48.0%
- 4-year CAGR
- +206.8%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.45M | -48.0% |
| FY2024 | 2024-12-31 | 14.32M | +32.7% |
| FY2023 | 2023-12-31 | 10.79M | +351.1% |
| FY2022 | 2022-12-31 | 2.39M | +2747.6% |
| FY2021 | 2021-12-31 | 84K | — |
Interest Income vs competitors
How ABOS compares with its peers on the latest reported figures
- ABOS's LTM Mar 2026 interest income of $6.04M is the 4th highest of the 10 companies compared; the peer median is $1.93M.
- Its year-over-year change of -52.7% is the 7th highest of 8, against a peer median of -31.2%.
- Over three fiscal years its annual growth of +46.0% compares with a peer median of +27.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $553.61M | +13486.2% | -20.3% | — | |
| LTM Mar 2026 | $10.53M | -31.2% | +35.8% | 70.0% | |
| LTM Mar 2026 | $9.58M | -41.8% | +23.7% | 151.7% | |
| LTM Mar 2026 | $6.04M | -52.7% | +46.0% | — | |
| LTM Mar 2026 | $1.98M | -53.6% | +31.4% | 3.6% | |
| LTM Mar 2026 | $1.93M | -34.2% | -10.0% | 168.6% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $800K | -24.7% | — | 6.7% |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $319.36K | +22.3% | +120.0% | — |
| LTM Mar 2026 | $21K | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ABOS) | $1.93M | -31.2% | +27.6% | 6.7% | |
Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 12.31M | 0 | 0 | 0 | 0 |
| Gross Profit | (12.31M) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.31M | 32.36M | 42.32M | 93.8M | 104.89M |
| Selling, General & Admin | 7.28M | 12.88M | 18.82M | 20.22M | 18.95M |
| Operating Expenses | 7.28M | 45.24M | 61.14M | 114.02M | 123.83M |
| Depreciation & Amortization | 4K | 169K | 184K | 178K | 184K |
| EBITDA | (100.6M) | (42.69M) | (51.61M) | (98.08M) | (116.93M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.58M) | (45.24M) | (61.14M) | (114.02M) | (123.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 84K | 2.39M | 10.79M | 14.32M | 7.45M |
| Interest Expense | 0 | 0 | 581K | 4.07M | 4.22M |
| Other Income / Expenses | (81.02M) | 2.38M | 8.77M | 11.69M | 2.5M |
| Income Before Tax | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| EPS (Diluted) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| Weighted Avg Shares | 38.27M | 40.6M | 48.49M | 60.01M | 60.56M |
| Weighted Avg Shares (Diluted) | 38.27M | 40.6M | 48.61M | 60.01M | 60.56M |
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Intrinsic Alpha fair value
Locked
Current Price
$2.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.